Perspective Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 06/30/22 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | $1.4M | $0 | $10.8M |
| Cost of revenue | — | — | — | — | $6.2M |
| Gross profit | — | — | $1.4M | $0 | $0 |
| Research and development | $84.2M | $41.6M | $21.3M | $881,000 | $850,000 |
| Operating expenses | $114.4M | $92.3M | $42.4M | $8.7M | $6.4M |
| Operating income | -$113.6M | -$90.9M | -$40.9M | -$8.7M | -$6.4M |
| Interest expense | — | — | $84,000 | $0 | $0 |
| Pretax income | -$104.4M | -$80.4M | -$40.1M | -$8.1M | -$6.3M |
| Income tax expense | -$793,000 | -$2.1M | -$2.7M | $0 | $0 |
| Net income | -$103.1M | -$79.3M | -$46.5M | -$10.8M | -$7.3M |
| Balance Sheet | |||||
| Cash and equivalents | $30.6M | $61.6M | $9.2M | $21.0M | $55.9M |
| Current assets | $148.4M | $231.2M | $16.8M | $53.2M | $59.3M |
| Total assets | $267.0M | $341.1M | $97.9M | $58.1M | $64.4M |
| Current liabilities | $28.7M | $18.2M | $15.7M | $3.1M | $2.3M |
| Total liabilities | $59.9M | $50.4M | $22.7M | $3.4M | $3.2M |
| Stockholders' equity | $207.0M | $290.7M | $75.2M | $54.6M | $61.3M |
| Cash Flow Statement | |||||
| Cash from operations | -$82.5M | -$18.3M | -$36.9M | -$10.4M | -$7.7M |
| Depreciation and amortization | $3.3M | $2.3M | $946,000 | $267,000 | $248,000 |
| Stock-based compensation | $9.0M | $5.4M | $3.7M | $983,000 | $1.1M |
| Capital expenditure | $12.7M | $54.4M | $1.1M | $282,000 | $266,000 |
| Free cash flow | -$95.2M | -$72.7M | -$38.0M | -$10.7M | -$8.0M |
| Impairments | $0 | $24.1M | $0 | — | — |
Shares outstanding 114.0M · Free float 96.9%
Annual filing data through FY ended December 31, 2025; float as of July 8, 2026.